Firmonertinib (mesylate)
Product Specifications
UNSPSC Description
Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation[1].
Target Antigen
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/firmonertinib-mesylate.html
Purity
99.97
Solubility
DMSO : 5 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
Molecular Weight
664.70
References & Citations
[1]Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial. |[2]Alexander I. Spira, et al. FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Journal of Clinical Oncology. Volume 42, Number 16_supplAdv Ther. 2024 Jul 18.|Patent. US20220177473A1.|JTO Clin Res Rep. 2023 Nov 27, 100614.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-112870A/Firmonertinib-mesylate-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-112870A/Firmonertinib-mesylate-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
2130958-55-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
